[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613148":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":37,"locations":43,"responsibleParty":59,"collaborators":63,"id":67,"slug":36,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":36,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":36,"overallStatus":86,"whyStopped":36,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Swiss Tropical & Public Health Institute","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Arpraziquantel 30 mg\u002Fkg","EXPERIMENTAL","Treatment with a single dose arpraziquantel: 30 mg\u002Fkg, orally administered",[13],"Drug: Apraziquantel",{"label":15,"type":10,"description":16,"interventionNames":17},"Arpraziquantel 40 mg\u002Fkg","Treatment with a single dose arpraziquantel: 40 mg\u002Fkg, orally administered",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Arpraziquantel 50 mg\u002Fkg","Treatment with a single dose arpraziquantel: 50 mg\u002Fkg, orally administered",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Arpraziquantel 60 mg\u002Fkg","Treatment with a single dose arpraziquantel: 60 mg\u002Fkg, orally administered",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Arpraziquantel 20 mg\u002Fkg","Treatment with a single dose arpraziquantel: 20 mg\u002Fkg, orally administered",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Apraziquantel","Tablets (dispersible) containing 150 mg arpraziquantel",[27,9,15,19,23],null,[38],{"name":39,"role":40,"phone":41,"phoneExt":36,"email":42},"Jennifer Keiser, PhD","CONTACT","+41 61 284 82 18","jennifer.keiser@swisstph.ch",[44],{"facility":45,"status":36,"city":46,"state":36,"zip":36,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Lao Tropical and Public Health Institute (Lao TPHI)","Vientiane","Laos",{"type":49,"coordinates":50},"Point",[51,52],102.6,17.96667,{"lat":52,"lon":51},[55],{"name":56,"role":40,"phone":57,"phoneExt":36,"email":58},"Somphou Sayasone, PhD","+856 20 556 79 603","somphou.sayasone@yahoo.com",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"SPONSOR_INVESTIGATOR","Jennifer Keiser","Prof. Dr.",[64],{"name":65,"class":66},"Lao Tropical and Public Health Institute","OTHER_GOV","100613148",false,"NCT07262814","Efficacy and Safety of Ascending Doses of Arpraziquantel in Children Infected With Opisthorchis Viverrini","Efficacy, Safety and Acceptability of Ascending Doses of Arpraziquantel for Opisthorchis Viverrini Infections in Children Aged 6-7 Years: A Single-blind Randomized Dose-ranging Trial","ADORA-VI","Inclusion Criteria:\n\n* Aged 6 to 7 years (i.e., 72 to 95 months).\n* Written informed consent signed by parents\u002Fcaregivers (signature or thumbprint).\n* Agree to comply with study procedures, including provision of two stool samples at baseline and at follow-up assessment 21-28 days after treatment, respectively.\n* Willing to be examined by a study physician prior to treatment.\n* At least two slides of the quadruple Kato-Katz thick smears positive for O. viverrini.\n\nExclusion Criteria:\n\n* Presence or signs of major systemic illness, e.g. severe anaemia (haemoglobin level of \\\u003C 80 g\u002FL according to WHO) upon initial clinical assessment.\n* Known or suspected infection with Taenia solium (cysticercosis).\n* Known or suspected acute schistosomiasis.\n* Abnormal liver and kidney function.\n* Use of anthelminthic drugs within 4 weeks before or during study period.\n* Known allergy to study medications (i.e. praziquantel or any of the excipients).\n* Being prescribed or taking concomitantly medication with known contraindication or drug interactions with the study medication.\n* Concurrent participation in other clinical trials.","ALL","6 Years","7 Years",{"count":78,"type":79},125,"ESTIMATED","INTERVENTIONAL",[82],"PHASE2","This study aims to assess the efficacy, safety and acceptability of ascending doses of arpraziquantel in children infected with Opisthorchis viverrini. The primary objective is to determine the dose-response relationship in terms of cure rate. This study will involve children aged 6-7 years, since O. viverrini infections often occur in pre-school and school-aged children, and this group is largely left untreated in current public health programs.",[85],"Opisthorchis Viverrini","NOT_YET_RECRUITING","2026-03-17",{"date":89,"type":90},"2026-03-20","ACTUAL",{"date":92,"type":79},"2026-04-15",{"date":94,"type":79},"2026-08",{"name":61,"class":6},1]